Introduction
Cancer is a challenging and terrifying disease and the most widely used treatment modalities are chemotherapy, radiotherapy, and surgery.
1−3 These treatment modalities frighten patients due to the side effects that to date have not been obviated. 4, 5 A novel treatment modality, photodynamic therapy, that has been used clinically for around 25 years has emerged and is widely used as an alternative method for treatment of malignant and nonmalignant diseases.
6,7
The photodynamic therapy strategy is based on the preferential localization of certain photosensitizers in tumor tissues upon systematic administration. After the administration of the photosensitizer into the body, the sensitizer is activated by red or near infrared light, which leads to generation of reactive oxygen species including singlet oxygen ( 1 O 2 ) , and thus irreversibly damaging the tumor cells. These photosensitizers are harmless in the absence of light and their phototoxicity mainly relies on the generation of singlet oxygen, which is converted from its triplet state to its singlet state by an excited-state dye. A convenient photodynamic therapy agent should have absorption maxima in the spectral region of 700-900 nm, which is known as the therapeutic window. Because of the fact that light arrays below 700 nm cannot penetrate deeply into the tissue and water in the body begins to absorb light above 900 nm, a well-designed photosensitizer should absorb light in the therapeutic window.
8,9
BODIPY (4, 4-difluoro-4-bora-3a, 4a-diaza-s-indacene) dyes have attracted much attention as photosensitizers in the last decade due to their characteristics, which are particularly required for effective photosensitizers and photodynamic action. The distinctive properties of BODIPY dyes such as photostability, high absorption coefficient, low dark toxicity, and singlet oxygen generation have inspired efforts to develop BODIPY-based photosensitizers. 10−18 Furthermore, BODIPY dyes have many desirable characteristics that are often superior to those of other photosensitizers (fluorescein, porphyrins, cyanines, etc.). These properties are good solubility in common organic solvents, easily modulable excitation, and ease of synthesis. 19 For instance, compared with porphyrin-type photosensitizers, BODIPY-type photosensitizers show intense absorption in the near-IR region of the electromagnetic spectrum, shorter periods of photosensitization, and low side-effect profiles (e.g., skin photosensitivity after irridation). 10, 20 Modifications on BODIPY cores may be carried out by introduction of different groups affording red-shifted BODIPY derivatives. 21 It was shown that the strongly electron-withdrawing group CF 3 at the meso position of the BODIPY core resulted in a large bathochromic shift by stabilizing the energy of the lowest unoccupied molecular orbital (LUMO) in comparison to that of congeners with aryl substituents in this position.
22−25
In the present study, our aim was to synthesize novel near-IR BODIPY-based photosensitizers containing the strongly electron-withdrawing group CF 3 at the meso position (C-8) of the BODIPY core. Incorporation in BODIPY cores of the heavy atoms that would give rise to effective singlet oxygen generation by intersystem crossing for serving as a potential photodynamic therapy agent was also aimed. 26 Hence, a general effective route to a novel family of meso-CF 3 -3,5-diaryl-BODIPY dyes composed of four different target BODIPY molecules was designed here.
Results and discussion

Synthesis of target molecules
In the present study, we designed and synthesized four novel photosensitizers. For the synthesis of these compounds, a novel protocol was applied. Firstly, 2-methyl pyrrole was synthesized via Wolff-Kishner reduction starting with pyrrole-2-carboxaldehyde. It was then treated with trifluoroacetic acid anhydride. After this step, the reaction mixture was dissolved in DCM. To obtain orange fluorescent meso-CF 3 -substituted BODIPY derivative 1, Et 3 N and BF 3 .OEt 2 were sequentially added to the medium, followed by stirring. With the goal of increasing singlet oxygen efficacy, the well-known heavy atoms iodine and bromine were introduced at the 2-and 6-positions of the BODIPY cores. Introduction of the heavy atom bromine was achieved by reacting NBS with compound 1 at room temperature, yielding compound 3. In a different protocol, compound 1 was treated with ICl to yield compound 2. It was recently shown that the presence of an electron-withdrawing group at the meso position of BODIPY cores gives rise to more acidic methyl groups at the 3-and 5-positions of the BODIPY cores and facile synthesis of distyryl-BODIPY derivatives. 27 Finally, in order to shift the maximum absorption of the targeted photosensitizers to the near-IR region of the electromagnetic spectrum, electron-donating terminal groups were introduced to the BODIPY cores via the Knoevenagel condensation reaction, which allows the extension of the conjugation at the same time. As mentioned above, the targeted photosensitizers 4, 5, 6, and 7 were obtained via Knoevenagel condensation with very short reaction times. The reaction scheme is given in Figure 1 . All new compounds were characterized by 1 H NMR and 13 C NMR spectroscopy and HRMS. The absorption spectra of the synthesized novel photosensitizers were recorded in DCM using a Varian spectrophotometer. As can be seen from Figure 2 , the targeted compounds 4, 5, 6, and 7 showed absorption maxima in the therapeutic window of the electromagnetic spectrum (886 nm, 890 nm, 760 nm, and 761 nm, respectively). The targeted photosensitizers show very weak emissions due to the presence of halogen atoms in their BODIPY cores. Furthermore, the presence of the strongly electron-withdrawing group CF 3 at the meso position of BODIPY cores decreases fluorescence drastically. Therefore, fluorescence quantum yields of the targeted compounds could not be measured as found in the literature. 28, 29 Attachment of the electron-donating group 4,4-dimethylaminobenzaldehyde to the meso-CF 3 -substituted and brominated BODIPY gave rise to a spectacular 304 nm red shift.
Singlet oxygen generation experiments by chemical trapping
It is a well-known fact that singlet oxygen is cytotoxic and can irreversibly damage malignant cancer cells or biological cell components such as proteins, lipids, and nucleic acids. 
Singlet oxygen generation experiment of compounds 4 and 5
It is noteworthy that for the first 15 min the cuvettes were kept in the dark and there was no discernible decrease in the absorbance spectrum of DPBF. The samples were then irradiated with an LED at 890 nm for 35 min (890 nm, fluence rate 2.5 mW/cm 2 ) . Absorbance was measured in 5-min intervals and the absorption of the trap molecule decreased. The results are given in Figures 3 and 4. 
Singlet oxygen generation experiment of compounds 6 and 7
The same protocol applied to determine the singlet oxygen generation capacity of compounds 4 and 5 was carried out. For the first 3 min, the samples were kept in the dark and there was no recognizable change in the absorption of DPBF in the absence of photosensitizers. It may be clearly seen in Figure 5 for compound 7.
Compound 7 was exposed to a near-IR light emitting diode (760 nm, fluence rate 2.5 mW/cm 2 ). The singlet oxygen generation process of compound 7 is shown in Figure 6 . Absorbance of DPBF was acquired in 1-min intervals and the absorption of the trap molecule decreased dramatically in the presence of compound 7.
Singlet oxygen quantum yield determination
Singlet oxygen quantum yields in DCM were calculated using a commonly used standard, methylene blue ( ϕ∆ = 0.57 in dichloromethane). 36 The change in the absorption of the trap molecule at 410 nm versus irradiation time was graphically demonstrated by plotting the data for compounds 6 and 7. The results are given in Figure 7 . It was noted that compounds 6 and 7 were highly effective singlet oxygen generators. As can be seen from the Table, singlet oxygen quantum yields of photosensitizers 4, 5, 6, and 7 were 0.10, 0.18, 0.52, and 0.93, respectively. Compounds 6 and 7 were more effective singlet oxygen generators in comparison to the conventional singlet oxygen generator methylene blue and previously reported BODIPY-based photosensitizers. 
Conclusion
In summary, a series of novel meso-CF 3 -substituted BODIPY derivatives were designed and synthesized. Gratifyingly, the novel BODIPY derivatives had absorption maxima in the therapeutic window of the electromagnetic spectrum. The introduction of electron-donating groups (4,4-dimethylaminobenzaldehyde and 4-(2 ethylhexyl)oxy benzaldehyde) at the 3-and 5-positions of the BODIPY cores and the attachment of an electronwithdrawing group to the 8-position of the BODIPY cores resulted in remarkable red shifts in the absorption and emission spectra. Compounds 6 and 7 show respectable singlet oxygen quantum yields in comparison to previously reported BODIPY-based photosensitizers. 37 Further studies into the synthesis of water-soluble meso-CF 3 -substituted and in vivo singlet oxygen generation experiments are ongoing at our laboratory to understand potential PDT applications.
Experimental
General
H NMR and
13 C NMR spectra were recorded on a Bruker DPX-400 (operating at 400 MHz for 1 H NMR and 100 MHz for 13 C NMR) in CDCl 3 with tetramethylsilane as the internal standard. All spectra were recorded at 25°C and the coupling constants (J values) are given in Hz. Chemical shifts are given in parts per million (ppm). Absorption spectra analyses were performed using a Varian Cary-100 spectrophotometer. Fluorescence measurements were conducted on a Varian Eclipse spectrofluorometer. Mass spectra were recorded on an Agilent Technologies 6530 Accurate-Mass Q-TOF LC/MS system. The reactions were monitored by thin layer chromatography using a Merck TLC Silica gel 60 F 254 set. Silica gel column chromatography was performed with Merck Silica gel 60 (particle size: 0.040-0.063 mm, 230-400 mesh ASTM). All other reagents and solvents were purchased from Aldrich and used without further purification. Singlet oxygen quantum yield values were calculated based on the following equation:
where bod and ref designate the orthogonal BODIPY photosensitizer and MB, respectively. m is the slope of the difference in change in the absorbance of DPBF (414 nm) with irradiation time, F is the absorption correction factor, which is given by F = 1 -10 −OD (OD at the irradiation wavelength), and PF is the absorbed photonic flux ( µ Einstein dm −3 s 1 ).
Synthesis of meso-CF 3 -substituted BODIPY (1)
Trifluoroacetic acid anhydride (5.85 mmol, 0.82 mL) was dropwise added into a 200-mL round bottom flask containing 2-methyl pyrrole (11.71 mmol, 950 mg). The reaction mixture was stirred for 20 min at room temperature. The combined organic mixture was dissolved in 200 mL of argon-degassed CH 2 Cl 2 and was stirred for 1 h. After that, to the reaction mixture were sequentially added 1.5 mL of Et 3 N and 1.5 mL of BF 3 .OEt 2, followed by stirring for 1 h. The resulting solution was washed three times with water and dried over anhydrous Na 2 SO 4 . The solvent was removed in vacuo and then silica gel column chromatography was carried out to purify the residue (as eluent CHCl 3 ). The orange-colored fraction was collected (495 mg, 29%). 
Synthesis of iodinated meso-CF 3− substituted BODIPY (2)
Compound 1 (100 mg, 1.47 mmol) was dissolved in 10 mL of DCM. ICl (2.21 mmol, 0.36 g) in 10 mL of DCM was added dropwise to the solution at room temperature. After stirring for 1 h, saturated Na 2 S 2 O 3 solution in water was added to the reaction mixture. The mixture was then extracted into CH 2 Cl 2 and it was dried over Na 2 SO 4 . The residue was purified by silica gel column chromatography (EtOAc). A brown liquid was obtained (0.55 g, 69% 
Synthesis of brominated meso-CF 3 -substituted BODIPY (3)
Compound 1 (100 mg, 0.35 mmol) was dissolved in a mixture of DMF/DCM (25 mL:25 mL). Then Nbromosuccinimide (185 mg, 1.04 mmol) was dissolved in DCM (25 mL), and it was added to the reaction mixture dropwise over 15 min. The reaction mixture was stirred at room temperature for 2 h. Following thin layer chromatography, the reaction was stopped, and the extraction was achieved with water and DCM. The organic phase was dried with Na 2 SO 4 and evaporated using a rotary evaporator. The purification was carried out with a silica gel column using a chloroform/hexane mixture (3:1 v/v). The fraction that contained brominated meso-CF 3 -substituted BODIPY was collected, and the solvent was then evaporated using a rotary evaporator (120 mg, 77% 
Synthesis of 3,5-distyryl 8-CF 3 -substituted BODIPY (7)
Compound 2 (0.185 mmol, 100 mg) and 4-(2-ethylhexyl) oxy-benzaldehyde (0.450 mmol, 105.61 mg) were dissolved in benzene (20 mL). To the reaction mixture were successively added piperidine (0.5 mL) and glacial acetic acid (0.5 mL), and the mixture was refluxed for 10 min. The progress of the reaction was monitored by TLC (eluent CHCl 3 /hexane) (1:1). The crude product was concentrated under vacuum. The progress of the reaction was monitored by TLC (eluent CHCl 3 /hexane) (1:1). The crude product was concentrated under vacuum and purified using silica gel column chromatography (eluent CHCl 3 /hexane) (1:1) (45 mg, 25% 
